



1/16




FIG. 1




FIG. 2A

3/16




FIG. 2B

4/16




FIG. 3



6/16




FIG. 5

7/16




FIG. 6

8/16




FIG. 7

9/16

SIMULATIONS SHOWING THAT IF THE PROTOCOL IS PRE-CALCULATED THEN A SIMILAR OR A
 HIGHER EFFICACY CAN BE OBTAINED USING 4-FOLD REDUCED TOTAL DOSE OF TPO.

TPO USE IN HEALTHY DONORS:




FIG. 8A

FIG. 8B

FIG. 8: TPO GIVEN TO HEALTHY DONORS- RESULTS OF TPO CLINICAL TRIALS FROM RECENT RESEARCH ON HEALTHY PLATELET DONORS, AS
 COMPARED TO OUR COMPUTER SIMULATION RESULTS. ARROWS INDICATE THE START OF TPO TREATMENT. (A) COMPARISON OF EXPERIMENTAL
 DATA FROM PUBLISHED ARTICLES¹ (BLACK) AND OUR MODEL SIMULATION (GREEN), IN BOTH TPO WAS GIVEN AS A SINGLE IV DOSE OF 1.2
 µg/kg ON DAY 0. (B) COMPARISON OF THE SAME EXPERIMENTAL DATA (BLACK) AND OUR PROPOSED TPO ADMINISTRATION PROTOCOL; THE
 TOTAL DOSE IN THE SIMULATED PROTOCOL WAS 0.3 µg/kg (BLUE).

10/16

SIMULATIONS SHOWING THAT IF THE PROTOCOL IS PRE-CALCULATED THEN A SIMILAR OR A HIGHER EFFICACY CAN BE OBTAINED USING 4-FOLD REDUCED TOTAL DOSE OF TPO.

TPO USE IN PATIENTS RECEIVING CHEMOTHERAPY:




FIG. 9A

FIG. 9B

FIG. 9: TPO WITH CHEMOTHERAPY- (A) RESULTS OF CLINICAL TRIALS FROM RECENT RESEARCH ON THROMBOCYTOPENIA INDUCED IN PATIENTS RECEIVING SINGLE CARBOPLATIN CHEMOTHERAPY² ON DAY 0 (BLACK), AS COMPARED TO OUR MODEL SIMULATION OF THESE RESULTS (GREEN). (B) THE SAME EXPERIMENTAL DATA (BLACK); SIMULATIONS OF THE SAME EXPERIMENT, WITH ADDITION OF "CONVENTIONAL" TPO PROTOCOL OF A SINGLE IV DOSE OF 1.2 μg/kg ON DAY 0 (OLIVE); SIMULATIONS OF THE SAME EXPERIMENT UNDER OUR PROPOSED PROTOCOL THAT TOTALS 0.3 μg/kg (BLUE).

11/16




FIG. 10

12/16




FIG. 11

13/16




FIG. 12B





FIG. 12A

14/16



15/16




FIG. 14

16/16




FIG. 15